Table 2. Anti-glycan mAbs and their inhibitory effects.

Anti-glycan mAbs	Glycan specificity	Inhibition of axon regeneration
		WT mice {No. of MF}	St8sia1-null mice {No. of MF}	B4galnt1-null mice {No. of MF}
Control Ab	None	No {2351±138 at SN; 576±62 at TN}	No {2379±227 at SN; 689±72 at TN}	No {1924±103 at SN; 529±42 at TN}
GD1a/GT1b-2b	GD1a/GT1b	Yes {354±50 (p < 0.05) at SN; 34±5 at TN (p < 0.05)}	Yes {254±19 (p < 0.05) at SN; 23±4 at TN (p < 0.05)}	No {1846±45 (p > 0.05) at SN; 496±14 at TN (p > 0.05)}
GD1a-1(E6 clone)	GD1a	No {2121±65 (p > 0.05) at SN; 535±71 at TN (p >0.05)}	Yes {792±116 (p < 0.05) at SN; 145±41 at TN (p < 0.05)}	No {2023±79 (p > 0.05) at SN; 523±30 at TN (p > 0.05)}
GD1a-2b	GD1a	No {2062±52 (p >0.05) at SN; 566±35 at TN (p >0.05)}	Yes {432±66 (p < 0.05) at SN; 48±8 at TN (p < 0.05)}	No {1937±101 (p > 0.05) at SN; 536±35 at TN (p > 0.05)}

The table contains the name of all anti-glycan mAbs used in the study, their glycan specificity, and their inhibitory effects on axon regeneration in WT and transgenic mice with altered ganglioside expression. Comparisons were made between control and anti-ganglioside Ab treated-animals, and the differences were determined using Student’s t-test. p < 0.05 was considered as significant. WT  =  wild type; MF  =  myelinated nerve fiber; SN  =  sciatic nerve; TN  =  tibial nerve; mAbs  =  monoclonal antibodies.